Peutz-Jeghers Syndrome (PJS) is a rare genetic disorder that is characterized by the presence of polyps in the gastrointestinal tract and dark spots on the skin. While the exact cause of PJS is unknown, research has suggested that it is caused by a genetic mutation. This article will explore the link between genetics and PJS, discussing the genetic mutation that is believed to cause the disorder, and the implications of this mutation for diagnosis and treatment.
Peutz-Jeghers Syndrome (PJS) is a rare genetic disorder that is characterized by the presence of polyps in the gastrointestinal tract and dark spots on the skin. The polyps are benign, meaning they are not cancerous, but they can cause problems with digestion and can lead to bleeding or blockages in the intestines. The dark spots are called “lentigines” and are caused by an increased number of melanocytes, the cells that produce pigment in the skin. PJS is usually diagnosed in childhood, but it can also be diagnosed in adulthood. The disorder is caused by a mutation in the STK11 gene, which is responsible for controlling cell growth. People with PJS have an increased risk of developing certain types of cancer, including colorectal, pancreatic, and gastric cancer.
The exact cause of PJS is unknown, but research has suggested that it is caused by a genetic mutation. The mutation occurs in the STK11 gene, which is responsible for controlling cell growth. People with PJS have an increased number of polyps in the gastrointestinal tract, as well as dark spots on the skin. The STK11 gene mutation is inherited in an autosomal dominant pattern, meaning that a person only needs one copy of the mutated gene to develop the disorder. People with PJS have a 50% chance of passing the mutated gene on to their children.
PJS can be difficult to diagnose, as the symptoms can be similar to other conditions. In order to diagnose PJS, doctors may perform genetic testing to look for the STK11 gene mutation. Additionally, doctors may perform an endoscopy or colonoscopy to look for the presence of polyps in the gastrointestinal tract. Once PJS is diagnosed, treatment typically involves monitoring the patient for any changes in the polyps or dark spots. Surgery may be recommended to remove any polyps that are causing problems. Additionally, people with PJS may be advised to undergo regular screening for certain types of cancer, as they are at an increased risk of developing these types of cancer.
Peutz-Jeghers Syndrome (PJS) is a rare genetic disorder that is caused by a mutation in the STK11 gene. This mutation is inherited in an autosomal dominant pattern, meaning that a person only needs one copy of the mutated gene to develop the disorder. PJS is characterized by the presence of polyps in the gastrointestinal tract and dark spots on the skin. Diagnosis of PJS involves genetic testing and endoscopy or colonoscopy, and treatment typically involves monitoring for changes in the polyps or dark spots, as well as regular screening for certain types of cancer.
1.
Cancer care crowdfunding increasingly common, but rarely successful
2.
First-Line HCC Trial's Lenvatinib-Pembrolizumab Combo Misses Target.
3.
Researchers discover that children who survive cancer have socioeconomic challenges.
4.
Could CT scans be fueling a future rise in cancer cases, as a new study suggests?
5.
SBRT May Beat Brachytherapy in Prostate Cancer
1.
Exploring the Normal Range of Monocytes: A Comprehensive Guide
2.
Breast Cancer Recovery: Fashion, Function, and Healing Beyond Scars
3.
Tailoring the Immune Response: The Dawn of Personalized Vaccines in Cancer Immunotherapy
4.
Value, Access, and Affordability in Next-Gen Oncology: Navigating Costs, Coverage, and Clinical Impact
5.
The Importance of Early Detection: How Genetics Play a Role in Leucocythemia Diagnosis
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A New Era in Managing Cancer-Associated Thrombosis
2.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
3.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation